Technology
Modeled by Cypre™: Proprietary hydrogel patterning technology builds consistent, high throughput 3D tumor models with complex biology such as T cell infiltration through the tumor stroma.
Schedule a Meeting
Connect with our business and scientific teams to explore strategic access and discuss how to drive your oncology innovation forward.
The Foundation of Translationally Relevant Preclinical Insights
Schedule a ConsultationKey Capabilities
Key Capabilities:
- Tumor/stroma/immune tri-culture models
- MOA analytics: high content imaging, cytokines, flow cytometry
- RNA-seq–enabled biomarker discovery
- IND-ready reporting formats
Representative Partner
- Use Cases Mechanism validation for bispecifics, ADCs, and I/O agents Preclinical biomarker hypothesis generation using matched response and multi omic data
- Exploration of responder/non-responder signatures Early insight into indication expansion or lead differentiation
Model Diversity (2025)
- NSCLC (n=15)
- CRC (n=5)
- Gastric (n=5)
- RCC (n=5)
- PDAC (n=5)
- Melanoma (n=5)
Precision Technology Built for the Next Generation of Oncology Therapeutics
Cypre’s patented 3D modeling platform—built on Symphony® and VersaGel®—enables physiologically complex tumor organoids that mimic the architecture and biology of the human tumor microenvironment (TME). By integrating stromal fibroblasts, ECM density, and immune components, our models capture key factors that drive therapeutic response in vivo. The result is a high-throughput, reproducible system that supports efficacy and MOA screening with the translational rigor required for IND-stage decision-making.
What Defines a Better Tumor Model?
Biological Complexity that Mirrors the Human TME
Our 3D tumor organoids incorporate stromal fibroblasts, ECM tuning, and immune compartments—including T cells, NK cells, macrophages, and B cells—capturing the cellular cross-talk and immune exclusion seen in real patient tumors. This level of physiological complexity is essential for modeling drug response and resistance mechanisms with translational relevance.
Predictive Across Modalities
Validated across chemotherapy, targeted therapies, immunotherapies, ADCs, and T cell engagers, our models are designed to reflect diverse treatment scenarios. Whether you're screening a single agent or a combination regimen, Cypre enables actionable insights for both early discovery and IND-stage programs.
Standardized Throughput at Scale
From high-content imaging to cytokine profiling and flow-based phenotyping, our platform supports standardized, multi-modal analytics—delivering reproducible data across models, timelines, and modalities. Turnaround times as fast as 30–45 days help accelerate decision-making without compromising data depth.
Accelerating Immunotherapy Insights with Complex 3D Tumor Models
Boehringer Ingelheim partnered with Cypre to evaluate a panel of T cell engagers across diverse PDX-derived tumor models—each designed to simulate an immune-excluded tumor microenvironment. The objective: assess tumor killing, T cell infiltration, and immune activation markers with greater physiological relevance than standard in vitro systems.
Using our proprietary VersaGel® hydrogel and standardized analytics, Cypre delivered detailed efficacy and MOA insights—including CD3⁺/CD8⁺ infiltration and cytokine profiles—in under 45 days. These results helped refine Boehringer’s lead optimization strategy and supported critical go/no-go decisions.
+
Models Screened across multiple tumor types using the Cypre 3D PDX platform
Multi-modal Analytics
High-content imaging, cytokines, and flow cytometry readouts delivered
Rapid Turnaround
Full reports returned within 6–9 weeks, supporting timely go/no-go decisions
Validated Insights
Data used in ongoing preclinical planning and pipeline strategy
FAQs
What makes Cypre’s 3D tumor models different from standard organoids or spheroids?
Can Cypre’s platform support IND-enabling studies?
What is the turnaround time for Cypre’s studies?
Can I screen my therapeutic across specific cancer types or genetic mutations?
How do I get started with a study or partnership?
Let’s Build the Future of Oncology, Together
Partner with Cypre to co-develop translationally validated, IND-ready insights using our complete 3D tumor organoid platform. From immune profiling to custom panels, we’re built for collaboration.
